This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Can IDEXX's (IDXX) International Growth Drive Q2 Earnings?
by Zacks Equity Research
In the United States, IDEXX (IDXX) witnesses a strong uptrend in CAG Diagnostic recurring revenues.
AmerisourceBergen (ABC) Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical Distribution and higher revenues are likely to aid AmerisourceBergen (ABC) in Q3 earnings.
Why Henry Schein (HSIC) Could Beat Earnings Estimates Again
by Zacks Equity Research
Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Henry Schein Closes Acquisition of Elite Computer Italia
by Zacks Equity Research
The Elite Computer acquisition marks Henry Schein's (HSIC) foray into the Italian dental practice management software market.
HSIC vs. WST: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HSIC vs. WST: Which Stock Is the Better Value Option?
What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
by Zacks Equity Research
Patterson Companies (PDCO) expects to gain from the Animal Health unit in fourth-quarter fiscal 2019.
HSIC vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. MMSI: Which Stock Is the Better Value Option?
Why Is Henry Schein (HSIC) Down 1.6% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medical Dental Supplies Industry Outlook: Growth Scope Wide
by Sreyoshi Mukherjee
Near-term prospects look bright for the Zacks Medical Dental Supplies industry, thanks to laser dentistry and robotics.
Henry Schein's (HSIC) Q1 Earnings, Revenues Beat Estimates
by Urmimala Biswas
Henry Schein's (HSIC) strong share gains in the North American market raise optimism.
Henry Schein (HSIC) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 5.26% and 0.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Dental Growth Drive Henry Schein's (HSIC) Q1 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is consistently riding on segmental strength at Dental, Medical and Technology plus Value-Added Services.
Analysts Estimate Henry Schein (HSIC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Henry Schein (HSIC) Up 2.1% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for March 21st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Henry Schein's New Buyout to Boost Dental Technology Business
by Zacks Equity Research
Henry Schein (HSIC) expects the acquisition to be neutral to its 2019 earnings per diluted share and accretive thereafter.
Henry Schien Buys North American Rescue, Expands Medical Arm
by Zacks Equity Research
Henry Schien (HSIC) believes that acquisition of NAR's business will offer multiple growth opportunities and promising business synergies.
Moving Average Crossover Alert: Henry Schein
by Zacks Equity Research
Henry Schein, Inc. (HSIC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Henry Schein's (HSIC) Q4 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
Strength in Henry Schein's (HSIC) global Medical and Technology and Value-added Services businesses in Q4 is encouraging.
Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is well placed to gain from digitalization in the global dental market.
Henry Schein (HSIC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein Animal Health Spin-Off Approaches, Costs Mount (revised)
by Zacks Equity Research
Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.
Near-Term Outlook for Dental Supplies Industry Looks Bright
by Zacks Equity Research
The wave of digital transformation is shaping the future of dental supply companies.
Henry Schein Animal Health Spin-Off Approaches, Cost Mounts
by Zacks Equity Research
Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.
Henry Schein (HSIC) Up 3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.